News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Garg Pushkal
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/07/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 4,518 shares
@ $0 Granted 3,109 shares
@ $0 Sold 658 shares
@ $184.7, valued at
$121.5k
Sold 1,593 shares
@ $185.54, valued at
$295.6k
Sold 945 shares
@ $186.39, valued at
$176.1k
Sold 86 shares
@ $187.37, valued at
$16.1k
Sold 15 shares
@ $188.4, valued at
$2.8k
Sold 164 shares
@ $189.31, valued at
$31k
Sold 3,112 shares
@ $183.58, valued at
$571.3k
Sold 814 shares
@ $184.65, valued at
$150.3k
Sold 240 shares
@ $185.32, valued at
$44.5k
|
|
08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
04/28/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 4,294 shares
@ $0 Sold 151 shares
@ $193.18, valued at
$29.2k
Sold 700 shares
@ $193.93, valued at
$135.8k
Sold 779 shares
@ $194.94, valued at
$151.9k
Sold 80 shares
@ $195.65, valued at
$15.7k
Sold 129 shares
@ $197.08, valued at
$25.4k
Sold 204 shares
@ $195.46, valued at
$39.9k
Sold 103 shares
@ $196.62, valued at
$20.3k
Sold 715 shares
@ $198.03, valued at
$141.6k
Sold 385 shares
@ $199.54, valued at
$76.8k
Sold 955 shares
@ $200.35, valued at
$191.3k
|
|
04/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/07/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Sold 18,072 shares
@ $200, valued at
$3.6M
Exercised 2,500 options to buy
@ $96.45, valued at
$241.1k
|
|
03/01/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 5,724 restricted stock units
@ $0 Granted 11,850 options to buy
@ $190.01, valued at
$2.3M
|
|
08/05/2022 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 4,518 shares
@ $0 Granted 3,684 shares
@ $0 Granted 3,109 shares
@ $0 Paid exercise price by delivering 4,603 shares
@ $189.76, valued at
$873.5k
Paid exercise price by delivering 165 shares
@ $205.87, valued at
$34k
Paid exercise price by delivering 172 shares
@ $209.91, valued at
$36.1k
Paid exercise price by delivering 146 shares
@ $210.02, valued at
$30.7k
|
|
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/04/2022 |
3
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 3 on ALNYLAM PHARMACEUTICALS, INC. |
06/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/30/2020 |
4
| Garg Pushkal (Director) has filed a Form 4 on SQZ Biotechnologies Co
Txns:
| Granted 7,055 options
@ $16, valued at
$112.9k
|
|
10/29/2020 |
3
| Garg Pushkal (Director) has filed a Form 3 on SQZ Biotechnologies Co |
|
|